RELIEF, a feasibility study, aims to evaluate the company’s irreversible electroporation (IRE) technology. Delivered by the company’s NanoKnife system, IRE already has FDA clearance for ablating prostate tissue associated with prostate cancer. Now,t he company has the green light to assess the technology in the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).

AngioDynamics says that current treatments for BPH range from pharmacologic therapy to surgical interventions and newer minimally invasive procedures.